The research and license collaboration is focused on Rigel’s preclinical small molecule compounds, which inhibit IgE receptor signaling in respiratory tract mast cells by blocking the signaling enzyme
The final agreements, signed on January 20, 2005, specify the purchase of 100% ownership of Biogenesis Ltd and Biogenesis Inc by MorphoSys for GBP5.25 million, less net debt
The FDA approved Vesicare in November 2004 for the treatment of overactive bladder with symptoms of urgency, frequency and urge incontinence in the US. When orally administered once
450 patients with symptomatic peripheral arterial obstructive disease (PAOD) and intermittent claudication (leg pain during walking) have been recruited. The phase II trial was designed with an independent
Ventavis (iloprost) was recently approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association class III or IV symptoms.
MCAA (monochloroacetic acid) is used in the manufacture of detergents, adhesives, textile auxiliaries and thickeners used in foods, pharmaceuticals and cosmetics. The fines are part of the commission’s
Sention will develop a family of Merck compounds known as mGluR5 antagonists as potential treatments for fragile X, the most commonly inherited form of mental retardation. The agreement
After reviewing the Exanta (ximelagatran) regulatory submission made in December 2003, the French Regulatory Authority (AFSSAPS) told AstraZeneca that it will require more information before the drug can
The H5N1 strain is a new strain of influenza virus that humans have little or no resistance to and has resulted in high rates of illness and death.
Seattle Genetics is currently conducting phase I clinical trials of SGN-40, an anti-CD40 antibody, in multiple myeloma and non-Hodgkin’s lymphoma. The company plans to initiate an additional phase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.